Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
about
Which anticholinergic drug for overactive bladder symptoms in adultsCurrent evaluation and treatment of nocturiaDoes fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?Review of fesoterodineHealth economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in SpainBehavioral treatment of insomnia: also effective for nocturia.Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective studyEmerging drugs for treatment of urinary incontinence.Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ERAn overview of the clinical use of antimuscarinics in the treatment of overactive bladderComparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.Overactive bladder, differential diagnosis, and clinical utility of fesoterodinePharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trialOveractive bladder - 18 years - Part IIUpdate on tolterodine extended-release for treatment of overactive bladderA Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.The medical treatment of overactive bladder, including current and future treatments.Nocturia: new directions.The evaluation and treatment of nocturia: a consensus statement.Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety.Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011.Efficacy assessments in randomized controlled studies of acute therapy for hereditary angioedema.Current pharmacotherapy of nocturia.Management of OAB in those over age 65.Evaluation of fesoterodine fumarate for the treatment of an overactive bladder.Fesoterodine fumarate and the oxybutynin ring for the treatment of urinary incontinence in women.Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.Urinary incontinence in the young woman: treatment plans and options available.Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.Emerging drugs for overactive bladder.Delivery methods for drugs used in the treatment of overactive bladder.Potential Primary Endpoint for Exploratory Clinical Trial in Patients with Overactive Bladder: A Systematic Literature Review.Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study.Clinical Guideline for Female Lower Urinary Tract Symptoms.Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.Fesoterodine prescription fill patterns and evaluation of the YourWay patient support plan for patients with overactive bladder symptoms and physicians.Early onset of fesoterodine efficacy in subjects with overactive bladder.Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.
P2860
Q24203880-840656E5-2060-4B5E-B0B9-B3973D91B4E6Q24631558-B94947B0-4BE2-45BC-8FCB-489A5155ED60Q27000698-616C5E2C-0CDF-4092-B211-F3124A82A134Q28239495-BA8F6FB9-225B-47CF-B3C5-A37FDA06842CQ33588346-CA5D0A84-F007-470A-B720-C7E855BFB746Q33748111-35A1DC09-5352-448B-ABE3-01C8E8BDD051Q34352604-CF36FD87-594B-4830-B950-F79682D3AFAEQ34618648-0288B179-F5B3-4464-9E28-B64C86C4D8D9Q34693256-A3EEF095-6EA2-4349-AD4B-DC62D4910D2BQ35042575-17EA7D0D-579F-463E-A4AA-95E390FE210AQ35183615-7274E2D2-FE6B-4BDA-8FDE-606391812167Q36429651-812D1F50-A69E-4D6C-B24F-7D0AD1C70FC8Q36603287-821358A9-00EC-49C7-807B-BA223A58B42EQ36912766-31BAD310-99EC-4C42-AFAA-A5F1F374E830Q37283585-A5AEE305-8C5D-44FD-B7D7-3BF3DEC53650Q37653402-65B9B2B9-5FDF-42FF-A425-E0ABB31B1A01Q37836943-380ABE0D-7FC8-41B5-8AB5-9B5E5DA7493DQ37887647-51755567-3E53-490D-9CEA-A2FF06986315Q37890031-673CBD27-82F5-4F7E-981D-B3B4BD97E8EEQ37947438-3A1CEF40-AA97-42C6-BFD0-32763C251193Q37992884-6D5327FF-AF5D-4EEB-9C36-353B2A843017Q37993502-3AA443B2-648C-497F-9058-A75EEC07E73AQ38026489-EC7680C7-DB02-43F6-B944-667D7B0FE713Q38095986-CFB5C8D3-25B9-4AB2-A66E-22E7346205EFQ38127155-D84F1695-CD09-4AA5-8F15-020EB56DB85BQ38160883-841DA58A-99F4-4317-9CFF-8510CA43E291Q38173919-D1C3AD1C-FD07-481C-B6D8-26E146CAE97DQ38190923-575AB227-B829-4199-88D7-BCA0C1A2C233Q38193878-59B6B76A-2E61-4F6F-B899-3B9938632EBEQ38352217-3E891B4F-7F69-4BC6-AD43-C5986A4558F8Q38584641-C15ACC25-057B-4443-88DD-0B76A2EF4F39Q38665319-911757F2-7B96-40E6-85C7-32639C94011BQ38993756-52588CE0-9A61-4AC7-8BB4-A91AE10660F9Q39020998-D2FEB5CE-A41F-42B2-8B7C-AAECD6BAD1EFQ39279571-4A8D2D1A-63F1-4EC5-9D3E-143A11BB1265Q40963346-10A100E9-8163-4395-9829-7F720E3AF6BAQ42626930-7219F6D5-B923-4DB4-81D5-AD358A697609Q42665431-F2930FA5-4300-44DE-830D-ACA653766EA9Q42676434-8C51D240-12E2-4B6E-BA34-DB4D367EDCBFQ42690377-62269F6B-6C9F-46EE-AA95-6DB2D9C0C818
P2860
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Comparison of fesoterodine and ...... head placebo-controlled trial.
@en
Comparison of fesoterodine and ...... head placebo-controlled trial.
@nl
type
label
Comparison of fesoterodine and ...... head placebo-controlled trial.
@en
Comparison of fesoterodine and ...... head placebo-controlled trial.
@nl
prefLabel
Comparison of fesoterodine and ...... head placebo-controlled trial.
@en
Comparison of fesoterodine and ...... head placebo-controlled trial.
@nl
P2093
P1433
P1476
Comparison of fesoterodine and ...... head placebo-controlled trial.
@en
P2093
Jason Gong
Jon D Morrow
Marina Brodsky
Martin Carlsson
Sender Herschorn
Steven Swift
Zhonghong Guan
P356
10.1111/J.1464-410X.2009.09086.X
P577
2010-01-01T00:00:00Z